120564-14-9

Basic information

• Product Name: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE
• Synonyms: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE;(S)-o-[(2,2-dimethyl-2,3-dioxolan-4-yl)methyl]-hydroxyamine HCl;(S)-O-[(2,2-DIMEHTYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE
• CAS NO: 120564-14-9
• Molecular Formula: C₆H₁₃NO₃
• Molecular Weight: 185.64914
• Mol File: 120564-14-9.mol

Chemical Properties

• Boiling Point: 220.2±15.0 °C(Predicted)
• Appearance: /
• Density: 1.048±0.06 g/cm3(Predicted)
• PKA: 4.07±0.70(Predicted)
• CAS DataBase Reference: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE(120564-14-9)
• EPA Substance Registry System: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE(120564-14-9)

Safety Data

• Hazardous Substances Data: 120564-14-9(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
(S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE is used as a reagent for the synthesis of various organic compounds, contributing to the advancement of chemical knowledge and the development of new materials and substances.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE is employed as a reagent in the synthesis of potential drug candidates, aiding in the discovery and development of novel therapeutic agents.
Used in the Study of Biological Processes:
(S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE is utilized in research to investigate biological processes and biochemical pathways, providing insights into the mechanisms of life and disease.
Used in Biochemical Pathway Research:
(S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE is applied in the study of biochemical pathways to understand the complex interactions and reactions within biological systems, which can lead to the identification of targets for therapeutic intervention.

Upstream product

• 131068-35-4 (S)-N-<(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy>phthalimide 
• 131068-34-3 (R)-2-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-isoindole-1,3-dione 
• 22323-82-6 (S)-(+)-(2,2-dimethyl-[1,3]dioxolan-4-yl)methanol 
• 14347-78-5 1,2-O-isopropylidene-D-glycerol 
• 60-34-4 methylhydrazine 
• 76679-39-5 [(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl trifluoromethanesulfonate 

Downstream Products

• 1009335-72-1 3-(2-fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-74-3 3-(2-fluoro-4-bromo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-75-4 3-(2-fluoro-4-iodo-phenylamino)-furo[2,3-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-76-5 3-(4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-79-8 3-(2-chloro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-81-2 3-(2,6-difluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-82-3 3-(2,5-difluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-87-8 7-bromo-3-(2-fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-89-0 5-(2-fluoro-4-iodo-phenylamino)-furo[2,3-d]pyrimidine-6-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-96-9 7-chloro-3-(2-fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 568600-10-2 N-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-benzamide 
• 391212-52-5 N-{[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide 
• 391210-10-9 PD0325901 
• 890043-39-7 C₂₁H₂₄BrN₅O₄ 

Relevant articles and documents

Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.

Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

The present disclosure relates to a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof, and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

TOPICAL FORMULATIONS

Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS

Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, Rl3a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS

Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (1), (II), (III), (IV), and (V). wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.

HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tauntomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans

Phosphomimetic sulfonamide and sulfonamidoxy analogues of (Lyso)phosphatidic acid

Lysophosphatidic acid (LPA) and phosphatidic acid (PA) are potent bioactive lipid mediators of signal transduction and are inactivated by phosphatases. To obtain receptor-isoform selective ligands with neutral phosphomimetic head groups, we performed the stereoselective synthesis of LPA and PA analogues with trifluoromethanesulfonamide and trifluoromethanesulfonamidoxy moieties replacing the phosphomonoester.

METHODS OF PREPARING MEK INHIBITOR

This invention relates to methods of preparing MEK inhibitor N-[(R)-2,3-dihydroxy-propoxy]-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide that useful for treating diseases mediated by MEK activity in mammals. The present invention provides new synthetic routes that are safe, efficient and cost effective when carried out on a commercial scale.

A new supported reagent for the parallel synthesis of primary and secondary O-alkyl hydroxylamines through a base-catalyzed Mitsunobu reaction

The growing field of applications of O-alkyl hydroxylamines in medicinal chemistry and chemical biology has motivated the search for a parallel synthesis. A solid-phase approach based on the alkylation by alcohols of a new supported N-hydroxyphthalimide reagent using a Mitsunobu reaction followed by methylaminolysis has been optimized. This study points out the importance of the linker and a specific base effect for the Mitsunobu reaction. A large variety of alcohols can be used to give with moderate to high yields diverse O-alkyl hydroxylamines in high purity.